CLINICAL_TRIALS
trial_result
· 2012-02-23
Clinical Trial Update: STUDY TO ASSESS THE LONG-TERM SAFETY OF EXTINA (KETOCONAZOLE) FOAM, 2% [Phase 4]
Summary
This Phase 4 trial update reports the long-term safety results of Extina (ketoconazole) 2% foam for seborrheic dermatitis.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Stiefel, a GSK Company | Conditions: Dermatitis, Seborrheic | Phase 4 | Status: COMPLETED | Results posted: 2012-02-23